1. PREFACE
1.1. Scope of the Report
1.2. Research Methodology
1.3. Chapter Outlines

2. EXECUTIVE SUMMARY

3. INTRODUCTION
3.1. Chapter Overview
3.2. Essential Components of ADCs
3.2.1. Antibody
3.2.2. Cytotoxin
3.2.3. Linker
3.3. ADC Manufacturing
3.3.1. Key Steps
3.3.2. Technical Challenges
3.3.3. Growing Trend of Contract Manufacturing
3.4. Challenges Associated with Supply Chain and Method Transfer
3.4.1. Growing Demand for One Stop Shops and Integrated Service Providers
3.5. Selecting a CMO Partner

4. ADC CONTRACT MANUFACTURERS: CURRENT MARKET LANDSCAPE
4.1. Chapter Overview
4.2. ADC Contract Manufacturers: Overall Market Landscape
4.2.1. Distribution by Location of Headquarters
4.2.2. Distribution by Year of Establishment
4.2.3. Distribution by Company Size
4.2.4. Distribution by Service(s) Offered
4.2.5. Distribution by Location of Manufacturing Facility
4.2.6. Distribution by Scale of Operation
4.2.7. Distribution by Other ADC Services Offered
4.3. Antibody Manufacturing Service Providers
4.4. HPAPI / Cytotoxic Drug Manufacturing Service Providers

5. COMPANY PROFILES
5.1. Chapter Overview
5.2. Abzena
5.2.1. Company Overview and Financial Information
5.2.2. ADC Offerings
5.2.3. Manufacturing Facilities
5.2.4. Recent Developments
5.2.5. Future Outlook
5.3. Ajinomoto Althea
5.3.1. Company Overview and Financial Information
5.3.2. ADC Offerings
5.3.3. Manufacturing Facilities
5.3.4. Recent Developments
5.3.5. Future Outlook
5.4. BSP Pharmaceuticals
5.4.1. Company Overview
5.4.2. ADC Offerings
5.4.3. Manufacturing Facilities
5.4.4. Recent Developments
5.4.5. Future Outlook
5.5. CARBOGEN AMCIS
5.5.1. Company Overview and Financial Information
5.5.2. ADC Offerings
5.5.3. Manufacturing Facilities
5.5.4. Recent Developments
5.5.5. Future Outlook
5.6. Catalent Pharma Solutions
5.6.1. Company Overview and Financial Information
5.6.2. ADC Offerings
5.6.3. Manufacturing Facilities
5.6.4. Recent Developments
5.6.5. Future Outlook
5.7. Cerbios-Pharma
5.7.1. Company Overview and Financial Information
5.7.2. ADC Offerings
5.7.3. Manufacturing Facilities
5.7.4. Recent Developments
5.7.5. Future Outlook
5.8. Creative Biolabs
5.8.1. Company Overview
5.8.2. ADC Offerings
5.8.3. Manufacturing Facilities
5.8.4. Recent Developments
5.8.5. Future Outlook
5.9. Goodwin Biotechnology
5.9.1. Company Overview
5.9.2. ADC Offerings
5.9.3. Manufacturing Facilities
5.9.4. Recent Developments
5.9.5. Future Outlook
5.10. Levena Biopharma
5.10.1. Company Overview
5.10.2. ADC Offerings
5.10.3. Manufacturing Facilities
5.10.4. Recent Developments
5.10.5. Future Outlook
5.11. Lonza
5.11.1. Company Overview and Financial Information
5.11.2. ADC Offerings
5.11.3. Manufacturing Facilities
5.11.4. Recent Developments
5.11.5. Future Outlook
5.12. MabPlex
5.12.1. Company Overview
5.12.2. ADC Offerings
5.12.3. Manufacturing Facilities
5.12.4. Recent Developments
5.12.5. Future Outlook
5.13. Merck (SAFC)
5.13.1. Company Overview and Financial Information
5.13.2. ADC Offerings
5.13.3. Manufacturing Facilities
5.13.4. Recent Developments
5.13.5. Future Outlook
5.14. Novasep
5.14.1. Company Overview and Financial Information
5.14.2. ADC Offerings
5.14.3. Manufacturing Facilities
5.14.4. Recent Developments
5.14.5. Future Outlook
5.15. Pierre Fabre
5.15.1. Company Overview and Financial Information
5.15.2. ADC Offerings
5.15.3. Manufacturing Facilities
5.15.4. Recent Developments
5.15.5. Future Outlook
5.16. Piramal Pharma Solutions
5.16.1. Company Overview and Financial Information
5.16.2. ADC Offerings
5.16.3. Manufacturing Facilities
5.16.4. Recent Developments
5.16.5. Future Outlook
5.17. Syngene
5.17.1. Company Overview and Financial Information
5.17.2. ADC Offerings
5.17.3. Manufacturing Facilities
5.17.4. Recent Developments
5.17.5. Future Outlook
5.18. WuXi Biologics
5.18.1. Company Overview and Financial Information
5.18.2. ADC Offerings
5.18.3. Manufacturing Facilities
5.18.4. Recent Developments
5.18.5. Future Outlook

6. COMPANY COMPETITIVENESS ANALYSIS
6.1. Chapter Overview
6.2. Methodology
6.2.1. Assumptions and Parameters Evaluated
6.3. Affiliated Insights
6.3.1. Spider Web Competitive Analysis: Abzena
6.3.2. Spider Web Competitive Analysis: Cambrex
6.3.3. Spider Web Competitive Analysis: Cerbios-Pharma
6.3.4. Spider Web Competitive Analysis: Merck (SAFC)
6.3.5. Spider Web Competitive Analysis: Novasep
6.3.6. Spider Web Competitive Analysis: Pierre Fabre
6.3.7. Spider Web Competitive Analysis: Piramal Pharma Solutions
6.3.8. Spider Web Competitive Analysis: WuXi Biologics

7. ADC CONTRACT MANUFACTURERS: FACILITY EXPANSIONS
7.1. Chapter Overview
7.2. ADC Contract Manufacturers: Recent Facility Expansions
7.2.1. Analysis by Year of Expansion
7.2.2. Analysis by Type of Expansion
7.2.3. Analysis by Type of Service Offered
7.2.4. Analysis by Type of Service and Year of Expansion
7.2.5. Analysis by Scale of Operation
7.2.6. Analysis by Location of Facility
7.2.7. Analysis by Scale of Operation and Location of Facility
7.2.8. Analysis by Key Players and Type of Expansion

8. ADC CONTRACT MANUFACTURERS: RECENT PARTNERSHIPS AND COLLABORATIONS
8.1. Chapter Overview
8.2. Partnership Models
8.3. ADC Contract Manufacturers: List of Partnerships and Collaborations
8.3.1. Analysis by Year of Partnership
8.3.2. Analysis by Type of Partnership
8.3.3. Key Players by Number of Partnerships
8.3.4. Regional Analysis
8.3.4.1. Most Active Players
8.3.4.2. Intercontinental and Intracontinental Agreements

9. ADC MANUFACTURING: CAPACITY ANALYSIS
9.1. Chapter Overview
9.2. Key Assumptions and Methodology
9.3. ADC Manufacturing: Overall Installed Global Capacity
9.3.1. Distribution by Size of Manufacturers
9.3.2. Distribution by Key Players
9.3.3. Distribution by Headquarters of Manufacturers
9.3.4. Distribution by Location of Manufacturing Facilities
9.3.4.1 By Country
9.3.4.2. By Continent

10. ADC THERAPEUTICS: MARKET OVERVIEW
10.1. Chapter Overview
10.2. ADC Therapeutics: Clinical Pipeline
10.2.1. Distribution by Phase of Development
10.2.2. Distribution by Indication
10.2.3. Distribution by Linker Type
10.2.4. Distribution by Payload Type
10.2.5. Distribution of Technology Providers by Number of Molecules
10.3. ADC Therapeutics: Preclinical / Discovery Pipeline
10.3.1. Distribution of Leading Players by Number of Molecules

11. ADC CONJUGATION TECHNOLOGY PLATFORMS
11.1. Chapter Overview
11.2. First Generation ADC Technologies
11.3. Second Generation ADC Technologies
11.3.1. Cysteine and Selenocysteine Engineering
11.3.2. Unnatural Amino Acid Engineering
11.3.3. Amino-Terminal Serine Engineering
11.4. Third Generation ADC Technologies
11.4.1. Enzyme-Assisted Ligation Approaches
11.4.2. Glycan Remodeling Approaches
11.4.3. Ligation at Fab Nucleotide-Binding Site
11.4.4. Cysteine Rebridging
11.4.5. Avoiding or Limiting Retro-Michael Drug Deconjugation
11.5. Evolutionary Analysis

12. GEOGRAPHICAL CLINICAL TRIALS ANALYSIS
12.1. Chapter Overview
12.2. Scope and Methodology
12.3. ADC Therapeutics: Overall Clinical Trial Analysis
12.3.1. Analysis by Trial Registration Year
12.3.2. Geographical Analysis by Number of Clinical Trials
12.3.3. Geographical Analysis by Enrolled Patient Population
12.4. ADC Therapeutics: Clinical Trial Analysis by Payload Type
12.4.1. Auristatin based Molecules
12.4.1.1. Geographical Analysis by Trial Phase and Recruitment Status
12.4.1.2. Geographical Analysis by Enrolled Patient Population
12.4.1.3. Analysis by Duration of Clinical Trials
12.4.2. Maytansinoid based Molecules
12.4.2.1. Geographical Analysis by Trial Phase and Recruitment Status
12.4.2.2. Geographical Analysis by Enrolled Patient Population
12.4.2.3. Analysis by Duration of Clinical Trials
12.4.3. Calicheamicin based Molecules
12.4.3.1. Geographical Analysis by Trial Phase and Recruitment Status
12.4.3.2. Geographical Analysis by Enrolled Patient Population
12.4.3.3. Analysis by Duration of Clinical Trials
12.4.4. PBDs (talirine, tesirine) based Molecules
12.4.4.1. Geographical Analysis by Trial Phase and Recruitment Status
12.4.4.2. Geographical Analysis by Enrolled Patient Population
12.4.4.3. Analysis by Duration of Clinical Trials
12.4.5. Duocarmycin based Molecules
12.4.5.1. Geographical Analysis by Trial Phase and Recruitment Status
12.4.5.2. Geographical Analysis by Enrolled Patient Population
12.4.5.3. Analysis by Duration of Clinical Trials
12.4.6. DXd (exatecan Derivative) based Molecules
12.4.6.1. Geographical Analysis by Trial Phase and Recruitment Status
12.4.6.2. Geographical Analysis by Enrolled Patient Population
12.4.6.3. Analysis by Duration of Clinical Trials
12.4.7. Molecules having Other Types of Payloads
12.4.7.1. Geographical Analysis by Trial Phase and Recruitment Status
12.4.7.2. Geographical Analysis by Enrolled Patient Population
12.4.7.3. Analysis by Duration of Clinical Trials
12.5. ADC Therapeutics: Clinical Trial Analysis by Linker Type
12.5.1. VC based Molecules
12.5.1.1. Geographical Analysis by Trial Phase and Recruitment Status
12.5.1.2. Geographical Analysis by Enrolled Patient Population
12.5.1.3. Analysis by Duration of Clinical Trials
12.5.2. Hydrazone Linker based Molecules
12.5.2.1. Geographical Analysis by Trial Phase and Recruitment Status
12.5.2.2. Geographical Analysis by Enrolled Patient Population
12.5.2.3. Analysis by Duration of Clinical Trials
12.5.3. SMCC based Molecules
12.5.3.1. Geographical Analysis by Trial Phase and Recruitment Status
12.5.3.2. Geographical Analysis by Enrolled Patient Population
12.5.3.3. Analysis by Duration of Clinical Trials
12.5.4. VA based Molecules
12.5.4.1. Geographical Analysis by Trial Phase and Recruitment Status
12.5.4.2. Geographical Analysis by Enrolled Patient Population
12.5.4.3. Analysis by Duration of Clinical Trials
12.5.5. SPDB based Molecules
12.5.5.1. Geographical Analysis by Trial Phase and Recruitment Status
12.5.5.2. Geographical Analysis by Enrolled Patient Population
12.5.5.3. Analysis by Duration of Clinical Trials
12.5.6. Molecules having Other Types of Linkers
12.5.6.1. Geographical Analysis by Trial Phase and Recruitment Status
12.5.6.2. Geographical Analysis by Enrolled Patient Population
12.5.6.3. Analysis by Duration of Clinical Trials

13. ADC THERAPEUTICS: DEMAND ANALYSIS
13.1. Chapter Overview
13.2. Key Assumptions and Methodology
13.3. ADC Therapeutics: Overall Annual Demand
13.3.1. ADC Therapeutics: Annual Commercial Demand
13.3.1.1. Distribution by Payload Type
13.3.1.2. Distribution by Linker Type
13.3.1.3. Distribution by Target Cancer Type
13.3.2. ADC Therapeutics: Annual Clinical Demand
13.3.2.1. Distribution by Phase of Development
13.3.2.2. Distribution by Payload Type
13.3.2.3. Distribution by Linker Type
13.3.2.4. Distribution by Target Cancer Type
13.3.2.5. Distribution by Region
13.4. ADC Therapeutics: Demand and Supply Analysis

14. MARKET SIZING AND OPPORTUNITY ANALYSIS
14.1. Chapter Overview
14.2. Forecast Methodology
14.3. Overall ADC Therapeutics Market, 2018-2030
14.4. Input Data and Key Assumptions
14.5. Overall ADC Contract Manufacturing Market, 2018-2030
14.5.1. ADC Contract Manufacturing Market, 2018-2030: Distribution by Component / Process Type
14.5.2. ADC Contract Manufacturing Market, 2018-2030: Distribution by Scale of Operation
14.6. ADC Contract Manufacturing Market for Commercial Products, 2018-2030
14.6.1. ADC Contract Manufacturing Market for Commercial Products, 2018-2030: Distribution by Component / Process Type
14.6.2. ADC Contract Manufacturing Market for Commercial Products, 2018-2030: Distribution by Payload Type
14.6.3. ADC Contract Manufacturing Market for Commercial Products, 2018-2030: Distribution by Linker Type
14.6.4. ADC Contract Manufacturing Market for Commercial Products, 2018-2030: Distribution by Target Cancer Type
14.6.5. ADC Contract Manufacturing Market for Commercial Products, 2018-2030: Distribution by Region
14.7. ADC Contract Manufacturing Market for Clinical Products, 2018-2030
14.7.1. ADC Contract Manufacturing Market for Clinical Products, 2018-2030: Distribution by Component / Process Type
14.7.2. ADC Contract Manufacturing Market for Clinical Products, 2018-2030: Distribution by Payload Type
14.7.3. ADC Contract Manufacturing Market for Clinical Products, 2018-2030: Distribution by Linker Type
14.7.4. ADC Contract Manufacturing Market for Clinical Products, 2018-2030: Distribution by Target Cancer Type
14.7.5. ADC Contract Manufacturing Market for Clinical Products, 2018-2030: Distribution by Region

15. SWOT ANALYSIS
15.1. Chapter Overview
15.1.1. Strengths
15.1.2. Weaknesses
15.1.3. Opportunities
15.1.4. Threats

16. CONCLUSION
16.1. Given the Growing Pipeline of ADC Therapeutics and Associated Manufacturing Challenges, Outsourcing is Considered to be a Viable Business Strategy in this Domain
16.2. Current Market Landscape is Relatively Niche with a Limited Number of Companies Offering End-To-End Services and a Few Players Providing Services at Commercial Scale
16.3. To Keep Pace with the Growing Demand for ADC Therapeutics, Many Contract Manufacturers Have Made Investments or Entered Into Strategic Alliances to Expand Existing Capabilities
16.4. Several Clinical Trials are being Conducted to Evaluate ADC Therapeutics Worldwide, the Majority of Such Studies are Centered in the US
16.5. Owing to the Presence of Several Small Companies and Start-Ups, the Trend of Outsourcing Such Operations is Likely to Flourish in the Coming Years
16.6. The Installed Capacity is Sufficient to Meet the Current Annual Demand; However, as The Demand Rises, CMOs will be Required to Invest in Installing Incremental Capacity

17. INTERVIEW TRANSCRIPTS
17.1. Chapter Overview
17.2. Aldo Braca, Chief Executive Officer and Giorgio Salciarini, Technical Business Development Manager, BSP Pharmaceuticals
17.3. Anthony DeBoer, Director, Business Development, Synaffix
17.4. Christian Bailly, Director of CDMO, Pierre Fabre
17.5. Christian Rohlff, Chief Executive Officer & Founder, Oxford BioTherapeutics
17.6. Jennifer L. Mitcham, Director, Business Development and Stacy McDonald, Group Product Manager, Catalent Pharma Solutions
17.7. John Burt, Chief Executive Officer, Abzena
17.8. Laurent Ducry, Head of Bioconjugates Commercial Development, Lonza
17.9. Mark Wright, Site Head, Piramal Healthcare
17.10. Sasha Koniev, Chief Executive Officer & Co-Founder, Syndivia
17.11. Anonymous, Director, Business Development, Leading CMO
17.12. Anonymous, Chief Executive Officer, Leading CMO

18. APPENDIX 1: TABULATED DATA

19. APPENDIX 2: LIST OF COMPANIES AND ORGANIZATIONS

List of Tables
Table 3.1 Commonly used Cytotoxins for ADC Therapeutics
Table 3.2 OEL Bands, Safebridge Consultants
Table 4.1 ADC Contract Manufacturers: List of Service Providers
Table 4.2 ADC Contract Manufacturers: Services Offered
Table 4.3 ADC Contract Manufacturers: Details on Manufacturing Facilities
Table 4.4 ADC Contract Manufacturers: Details on Scale of Production and Capacity
Table 4.5 ADC Contract Manufacturers: Details on Other Services Offered
Table 4.6 ADC Contract Manufacturers: List of Antibody Manufacturing Service Providers
Table 4.7 ADC Contract Manufacturers: List of HPAPI and Cytotoxic Drug Manufacturing Service Providers
Table 5.1 Abzena: Company Overview and Financial Information
Table 5.2 Abzena: ADC Related Offerings
Table 5.3 Abzena: Manufacturing Facilities Information
Table 5.4 Abzena: Recent Developments
Table 5.5 Abzena: Future Outlook
Table 5.6 Ajinomoto Althea: Company Overview and Financial Information
Table 5.7 Ajinomoto Althea: ADC Related Offerings
Table 5.8 Ajinomoto Althea: Manufacturing Facilities Information
Table 5.9 Ajinomoto Althea: Recent Developments
Table 5.10 Ajinomoto Althea: Future Outlook
Table 5.11 BSP Pharmaceuticals: Company Overview
Table 5.12 BSP Pharmaceuticals: ADC Related Offerings
Table 5.13 BSP Pharmaceuticals: Manufacturing Facilities Information
Table 5.14 BSP Pharmaceuticals: Recent Developments
Table 5.15 BSP Pharmaceuticals: Future Outlook
Table 5.16 CARBOGEN AMCIS: Company Overview and Financial Information
Table 5.17 CARBOGEN AMCIS: ADC Related Offerings
Table 5.18 CARBOGEN AMCIS: Manufacturing Facilities Information
Table 5.19 CARBOGEN AMCIS: Recent Developments
Table 5.20 Catalent Pharma Solutions: Company Overview and Financial Information
Table 5.21 Catalent Pharma Solutions: ADC Related Offerings
Table 5.22 Catalent Pharma Solutions: Manufacturing Facilities Information
Table 5.23 Catalent Pharma Solutions: Recent Developments
Table 5.24 Catalent Pharma Solutions: Future Outlook
Table 5.25 Cerbios-Pharma: Company Overview and Financial Information
Table 5.26 Cerbios-Pharma: ADC Related Offerings
Table 5.27 Cerbios-Pharma: Manufacturing Facilities Information
Table 5.28 Cerbios-Pharma: Recent Developments
Table 5.29 Cerbios-Pharma: Future Outlook
Table 5.30 Creative Biolabs: Company Overview
Table 5.31 Creative Biolabs: ADC Related Offerings
Table 5.32 Creative Biolabs: Manufacturing Facilities Information
Table 5.33 Creative Biolabs: Recent Developments
Table 5.34 Creative Biolabs: Future Outlook
Table 5.35 Goodwin Biotechnology: Company Overview
Table 5.36 Goodwin Biotechnology: ADC Related Offerings
Table 5.37 Goodwin Biotechnology: Manufacturing Facilities Information
Table 5.38 Goodwin Biotechnology: Recent Developments
Table 5.39 Goodwin Biotechnology: Future Outlook
Table 5.40 Levena Biopharma: Company Overview
Table 5.41 Levena Biopharma: ADC Related Offerings
Table 5.42 Levena Biopharma: Manufacturing Facilities Information
Table 5.43 Levena Biopharma: Recent Developments
Table 5.44 Levena Biopharma: Future Outlook
Table 5.45 Lonza: Company Overview and Financial Information
Table 5.46 Lonza: ADC Related Offerings
Table 5.47 Lonza: Manufacturing Facilities Information
Table 5.48 Lonza: Recent Developments
Table 5.49 Lonza: Future Outlook
Table 5.50 MabPlex: Company Overview
Table 5.51 MabPlex: ADC Related Offerings
Table 5.52 MabPlex: Manufacturing Facilities Information
Table 5.53 MabPlex: Recent Developments
Table 5.54 MabPlex: Future Outlook
Table 5.55 Merck (SAFC): Company Overview and Financial Information
Table 5.56 Merck (SAFC): ADC Related Offerings
Table 5.57 Merck (SAFC): Manufacturing Facilities Information
Table 5.58 Merck (SAFC): Recent Developments
Table 5.59 Merck (SAFC): Future Outlook
Table 5.60 Novasep: Company Overview and Financial Information
Table 5.61 Novasep: ADC Related Offerings
Table 5.62 Novasep: Manufacturing Facilities Information
Table 5.63 Novasep: Recent Developments
Table 5.64 Novasep: Future Outlook
Table 5.65 Pierre Fabre: Company Overview and Financial Information
Table 5.66 Pierre Fabre: ADC Related Offerings
Table 5.67 Pierre Fabre: Manufacturing Facilities Information
Table 5.68 Pierre Fabre: Recent Developments
Table 5.69 Pierre Fabre: Future Outlook
Table 5.70 Piramal Pharma Solutions: Company Overview and Financial Information
Table 5.71 Piramal Pharma Solutions: ADC Related Offerings
Table 5.72 Piramal Pharma Solutions: Manufacturing Facilities Information
Table 5.73 Piramal Pharma Solutions: Recent Developments
Table 5.74 Piramal Pharma Solutions: Future Outlook
Table 5.75 Syngene: Company Overview and Financial Information
Table 5.76 Syngene: ADC Related Offerings
Table 5.77 Syngene: Information on Manufacturing Facilities
Table 5.78 Syngene: Recent Developments
Table 5.79 Syngene: Future Outlook
Table 5.80 WuXi Biologics: Company Overview and Financial Information
Table 5.81 WuXi Biologics: ADC Related Offerings
Table 5.82 WuXi Biologics: Manufacturing Facilities Information
Table 5.83 WuXi Biologics: Recent Developments
Table 5.84 WuXi Biologics: Future Outlook
Table 6.1 Company Competitiveness Analysis: Shortlisted Players
Table 6.2 Company Competitiveness Analysis: Spiderweb Parameters for Shortlisted Players
Table 7.1 ADC Contract Manufacturers: Recent Facility Expansions
Table 8.1 ADC Contract Manufacturing: Partnerships and Collaborations, 2012-2018
Table 8.2 ADC Contract Manufacturing Partnerships: Most Active Players
Table 9.1 ADC Manufacturing Installed Global Capacity: Sample Data Set
Table 9.2 ADC Manufacturing Installed Global Capacity: Sample Data Set (Average Capacity)
Table 9.3 ADC Manufacturing Installed Global Capacity in Grams: Total Capacity by Size of Manufacturers
Table 10.1 ADC Therapeutics: Clinical Pipeline
Table 10.2 ADC Therapeutics: Clinical Pipeline (Information on Linkers and Payloads)
Table 10.3 ADC Therapeutics: Preclinical / Discovery Pipeline
Table 11.1 Second Generation ADC Technologies: Cysteine and Selenocysteine Engineering
Table 11.2 Second Generation ADC Technologies: Unnatural Amino Acid Engineering
Table 11.3 Second Generation ADC Technologies: Amino-terminal Engineered Serine
Table 11.4 Third Generation ADC Technologies: Enzyme-Assisted Ligation Approaches
Table 11.5 Third Generation ADC Technologies: Glycan Remodeling Approaches
Table 11.6 Third Generation ADC Technologies: Enzyme-Assisted Ligation Approaches
Table 11.7 Third Generation ADC Technologies: Cysteine Rebridging
Table 11.8 Third Generation ADC Technologies: Avoiding or Limiting Retro-Michael Drug Deconjugation
Table 12.1 Geographical Clinical Trial Analysis (Auristatin Based Molecules): Duration of Trials
Table 12.2 Geographical Clinical Trial Analysis (Maytansinoid Based Molecules): Duration of Trials
Table 12.3 Geographical Clinical Trial Analysis (Calicheamicin Based Molecules): Duration of Trials
Table 12.4 Geographical Clinical Trial Analysis (PBDs Based Molecules): Duration of Trials
Table 12.5 Geographical Clinical Trial Analysis (Duocarmycin Based Molecules): Duration of Trials
Table 12.6 Geographical Clinical Trial Analysis (DXd Based Molecules): Duration of Trials
Table 12.7 Geographical Clinical Trial Analysis (Other Types of Payload based Molecules): Duration of the Trials
Table 12.8 Geographical Clinical Trial Analysis (VC based Molecules): Duration of the Trials
Table 12.9 Geographical Clinical Trial Analysis (Hydrazone Linker Based Molecules): Duration of Trials
Table 12.10 Geographical Clinical Trial Analysis (SMCC Based Molecules): Duration of Trials
Table 12.11 Geographical Clinical Trial Analysis (VA Based Molecules): Duration of Trials
Table 12.12 Geographical Clinical Trial Analysis (SPDB Based Molecules): Duration of Trials
Table 12.13 Other Types of Linkers based ADC Therapeutics: Duration of the Trials
Table 14.1 Late Stage ADCs: Development Status
Table 14.2 ADC Therapeutics: Outsourcing Activity for Late Stage Molecules
Table 18.1 ADC Contract Manufacturers: Distribution by Location of Headquarters
Table 18.2 ADC Contract Manufacturers: Distribution by Year of Establishment
Table 18.3 ADC Contract Manufacturers: Distribution by Company Size
Table 18.4 ADC Contract Manufacturers: Distribution by Services Offered
Table 18.5 ADC Contract Manufacturers: Distribution by Location of Headquarters and Services Offered
Table 18.6 ADC Contract Manufacturers: Distribution by Location of Manufacturing Facilities
Table 18.7 ADC Contract Manufacturers: Distribution by Scale of Operation
Table 18.8 ADC Contract Manufacturers: Distribution based on Other Services Offered
Table 18.9 ADC Contract Manufacturers: Facility Expansions, Distribution by Year, 2012-2018
Table 18.10 ADC Contract Manufacturers: Distribution by Type of Recent Facility Expansion
Table 18.11 ADC Contract Manufacturers: Facility Expansions, Distribution by Type of Service
Table 18.12 ADC Contract Manufacturers: Facility Expansions, Distribution by Type of Service and Year of Expansion
Table 18.13 ADC Contract Manufacturers: Facility Expansions, Distribution by Scale of Operation
Table 18.14 ADC Contract Manufacturers: Facility Expansions, Distribution by Location of Facility
Table 18.15 ADC Contract Manufacturers: Facility Expansions, Distribution by Scale of Operation and Location of Facility
Table 18.16 ADC Contract Manufacturers: Facility Expansions, Distribution by Key Players and Type of Expansion
Table 18.17 ADC Contract Manufacturing: Partnerships and Collaborations, Cumulative Trend by Year, 2012-2018
Table 18.18 ADC Contract Manufacturing: Partnerships and Collaborations, Distribution by Type of Partnership
Table 18.19 ADC Contract Manufacturing: Partnerships and Collaborations, Most Active Players
Table 18.20 ADC Contract Manufacturing: Partnerships and Collaborations, Regional Distribution
Table 18.21 ADC Contract Manufacturing: Partnerships and Collaborations, Intercontinental and Intracontinental Distribution
Table 18.22 Overall ADC Installed Manufacturing Capacity: Distribution by Size of Manufacturers
Table 18.23 Overall ADC Installed Manufacturing Capacity: Distribution by Key Players
Table 18.24 Overall ADC Installed Manufacturing Capacity: Distribution by Headquarters of Manufacturers
Table 18.25 Overall ADC Installed Manufacturing Capacity: Distribution by Location of Manufacturing Facilities (by Country)
Table 18.26 Overall ADC Installed Manufacturing Capacity: Distribution by Location of Manufacturing Facilities (by Continent)
Table 18.27 ADCs Clinical Pipeline: Distribution by Phase of Development
Table 18.28 ADCs Clinical Pipeline: Distribution by Indication
Table 18.29 ADCs Clinical Pipeline: Distribution by Type of Linker
Table 18.30 ADCs Clinical Pipeline: Distribution by Type of Warhead
Table 18.31 ADCs Clinical Pipeline: Distribution by Technology Providers
Table 18.32 ADCs Preclinical / Discovery Pipeline: Relative Distribution of Key Technology Providers
Table 18.33 ADC Therapeutics: Year-wise Trend of Clinical Trials
Table 18.34 Geographical Clinical Trial Analysis: Distribution by Number of Trials
Table 18.35 Geographical Clinical Trial Analysis: Distribution by Enrolled Patient Population
Table 18.36 Geographical Clinical Trial Analysis: Distribution by Payload Type
Table 18.37 Geographical Clinical Trial Analysis (Auristatin based Molecules): Distribution by Trial Phase and Recruitment Status
Table 18.38 Geographical Clinical Trial Analysis (Auristatin based Molecules): Distribution by Enrolled Patient Population
Table 18.39 Geographical Clinical Trial Analysis (Maytansinoid based Molecules): Distribution by Trial Phase and Recruitment Status
Table 18.40 Geographical Clinical Trial Analysis (Maytansinoid based Molecules): Distribution by Enrolled Patient Population
Table 18.41 Geographical Clinical Trial Analysis (Calicheamicin based Molecules): Distribution by Trial Phase and Recruitment Status
Table 18.42 Geographical Clinical Trial Analysis (Calicheamicin based Molecules): Distribution by Enrolled Patient Population
Table 18.43 Geographical Clinical Trial Analysis (PBDs based Molecules): Distribution by Trial Phase and Recruitment Status
Table 18.44 Geographical Clinical Trial Analysis (PBDs based Molecules): Distribution by Enrolled Patient Population
Table 18.45 Geographical Clinical Trial Analysis (Duocarmycin based Molecules): Distribution by Trial Phase and Recruitment Status
Table 18.46 Geographical Clinical Trial Analysis (Duocarmycin based Molecules): Distribution by Enrolled Patient Population
Table 18.47 Geographical Clinical Trial Analysis (DXd based Molecules): Distribution by Trial Phase and Recruitment Status
Table 18.48 Geographical Clinical Trial Analysis (DXd based Molecules): Distribution by Enrolled Patient Population
Table 18.49 Geographical Clinical Trial Analysis (Molecules having Other Types of Payloads): Distribution by Trial Phase and Recruitment Status
Table 18.50 Geographical Clinical Trial Analysis (Molecules having Other Types of Payload): Distribution by Enrolled Patient Population
Table 18.51 ADC Therapeutics: Geographical Clinical Trial Distribution by Linker Type
Table 18.52 Geographical Clinical Trial Analysis (VC based Molecules): Distribution by Trial Phase and Recruitment Status
Table 18.53 Geographical Clinical Trial Analysis (VC based Molecules): Distribution by Enrolled Patient Population
Table 18.54 Geographical Clinical Trial Analysis (Hydrazone Linker based Molecules): Distribution by Trial Phase and Recruitment Status
Table 18.55 Geographical Clinical Trial Analysis (Hydrazone Linker based Molecules): Distribution by Enrolled Patient Population
Table 18.56 Geographical Clinical Trial Analysis (SMCC based Molecules): Distribution by Trial Phase and Recruitment Status
Table 18.57 Geographical Clinical Trial Analysis (SMCC based Molecules): Distribution by Enrolled Patient Population
Table 18.58 Geographical Clinical Trial Analysis (VA based Molecules): Distribution by Trial Phase and Recruitment Status
Table 18.59 Geographical Clinical Trial Analysis (VA based Molecules): Distribution by Trial Phase and Recruitment Status
Table 18.60 Geographical Clinical Trial Analysis (SPDB based Molecules): Distribution by Trial Phase and Recruitment Status
Table 18.61 Geographical Clinical Trial Analysis (SPDB based Molecules): Distribution by Enrolled Patient Population
Table 18.62 Geographical Clinical Trial Analysis (Molecules having Other Types of Linkers): Distribution by Trial Phase and Recruitment Status
Table 18.63 Geographical Clinical Trial Analysis (Molecules having Other Types of Linkers): Distribution by Enrolled Patient Population
Table 18.64 ADC Therapeutics: Overall Annual Demand, 2018-2030 (in kgs)
Table 18.65 ADC Therapeutics: Overall Annual Demand, Distribution by Scale of Operation, 2018-2030 (in kgs)
Table 18.66 ADC Therapeutics: Overall Annual Commercial Demand, 2018-2030 (in kgs)
Table 18.67 Annual Commercial Demand: Distribution by Payload Type, 2018-2030 (in kgs)
Table 18.68 Annual Commercial Demand: Distribution by Linker Type, 2018-2030 (in kgs)
Table 18.69 Annual Commercial Demand: Distribution by Target Cancer Type, 2018-2030 (in kgs)
Table 18.70 ADC Therapeutics: Overall Annual Clinical Demand, 2018-2030 (in kgs)
Table 18.71 Annual Clinical Demand: Distribution by Phase of Development, 2018-2030 (in kgs)
Table 18.72 Annual Clinical Demand: Distribution by Payload Type, 2018-2030 (in kgs)
Table 18.73 Annual Clinical Demand: Distribution by Linker Type, 2018-2030 (in kgs)
Table 18.74 Annual Clinical Demand: Distribution by Target Cancer Type, 2018-2030 (in kgs)
Table 18.75 Annual Clinical Demand: Distribution by Region, 2018-2030 (in kgs)
Table 18.76 Overall ADC Therapeutics Market: Conservative, Base and Optimistic Scenarios, 2018-2030 (USD Billion)
Table 18.77 ADC Therapeutics: Relative Cost of Manufacturing by Component / Process Type
Table 18.78 ADC Contract Manufacturing Market, 2018-2030: Distribution by Component / Process Type (USD Million), Conservative, Base and Optimistic Scenarios
Table 18.79 ADC Contract Manufacturing Market, 2018-2030: Distribution by Scale of Operation (USD Million), Conservative, Base and Optimistic Scenarios
Table 18.80 ADC Contract Manufacturing Market for Commercial Products, 2018-2030: Distribution by Component / Process Type (USD Million), Conservative, Base and Optimistic Scenarios
Table 18.81 ADC Contract Manufacturing Market for Commercial Products, 2018-2030: Distribution by Payload Type (USD Million), Conservative, Base and Optimistic Scenarios
Table 18.82 ADC Contract Manufacturing Market for Commercial Products, 2018-2030: Distribution by Linker Type (USD Million), Conservative, Base and Optimistic Scenarios
Table 18.83 ADC Contract Manufacturing Market for Commercial Products, 2018-2030: Distribution by Target Cancer Type (USD Million), Conservative, Base and Optimistic Scenarios
Table 18.84 ADC Contract Manufacturing Market for Commercial Products, 2018-2030: Distribution by Region (USD Million), Conservative, Base and Optimistic Scenarios
Table 18.85 ADC Contract Manufacturing Market for Clinical Products, 2018-2030: Distribution by Components of ADC (USD Million), Conservative, Base and Optimistic Scenarios
Table 18.86 ADC Contract Manufacturing Market for Clinical Products, 2018-2030: Distribution by Payload Type (USD Million), Conservative, Base and Optimistic Scenarios
Table 18.87 ADC Contract Manufacturing Market for Clinical Products, 2018-2030: Distribution by Linker Type (USD Million), Conservative, Base and Optimistic Scenarios
Table 18.88 ADC Contract Manufacturing Market for Clinical Products, 2018-2030: Distribution by Target Cancer Type (USD Million), Conservative, Base and Optimistic Scenarios

Please contact our Customer Support Center to get the complete Table of Contents